IXHL
vs
S&P 500
IXHL
S&P 500
Over the past 12 months, IXHL has underperformed S&P 500, delivering a return of -88% compared to the S&P 500's +18% growth.
Stocks Performance
IXHL vs S&P 500
Performance Gap
IXHL vs S&P 500
Performance By Year
IXHL vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Incannex Healthcare Ltd
Glance View
Incannex Healthcare Ltd. is a cannabinoid and psychedelic compound medicine development company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2007-05-23. The company is a clinical stage pharmaceutical development company. The firm is engaged in developing medicinal cannabis pharmaceutical products and psychedelic medicine therapies. Its product candidate IHL-42X is developing a combination of acetazolamide and dronabinol to reduce the apnea hypopnea index (AHI), IHL-216A is a combination of isoflurane and CBD to prevent development of traumatic brain injury (TBI)/concussion, HL-675A comprises a combination of hydroxychloroquine and CBD in prevention and treatment of inflammatory lung conditions (ARDS, COPD, asthma, and bronchitis), rheumatoid arthritis and inflammatory bowel diseases and Psi-GAD is providing Psychedelic-assisted psychotherapy for Generalized Anxiety Disorder (GAD).
